CN101824084A - Targeting antiglioma protein and application thereof - Google Patents
Targeting antiglioma protein and application thereof Download PDFInfo
- Publication number
- CN101824084A CN101824084A CN201010144841A CN201010144841A CN101824084A CN 101824084 A CN101824084 A CN 101824084A CN 201010144841 A CN201010144841 A CN 201010144841A CN 201010144841 A CN201010144841 A CN 201010144841A CN 101824084 A CN101824084 A CN 101824084A
- Authority
- CN
- China
- Prior art keywords
- protein
- cys
- bmk
- cltx
- mmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 41
- 230000001348 anti-glioma Effects 0.000 title claims abstract description 16
- 230000008685 targeting Effects 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 235000018102 proteins Nutrition 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 210000004498 neuroglial cell Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 13
- 239000001257 hydrogen Substances 0.000 abstract description 13
- 102000011045 Chloride Channels Human genes 0.000 abstract description 11
- 108010062745 Chloride Channels Proteins 0.000 abstract description 11
- 239000003053 toxin Substances 0.000 abstract description 11
- 231100000765 toxin Toxicity 0.000 abstract description 11
- 238000004458 analytical method Methods 0.000 abstract description 10
- 238000000329 molecular dynamics simulation Methods 0.000 abstract description 9
- 238000013461 design Methods 0.000 abstract description 6
- 208000032612 Glial tumor Diseases 0.000 abstract description 5
- 206010018338 Glioma Diseases 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000370 acceptor Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 7
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 241000239226 Scorpiones Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000009881 electrostatic interaction Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000005421 electrostatic potential Methods 0.000 description 5
- 241001481692 Mesobuthus martensii Species 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 210000001503 joint Anatomy 0.000 description 4
- 238000005381 potential energy Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002795 scorpion venom Substances 0.000 description 4
- 101710157325 Chloride channel protein C Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 241000239311 Buthus Species 0.000 description 2
- 101100067721 Caenorhabditis elegans gly-3 gene Proteins 0.000 description 2
- 101710091667 Chloride channel protein 2 Proteins 0.000 description 2
- 102100023509 Chloride channel protein 2 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 2
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 description 2
- 241000446313 Lamella Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000002919 insect venom Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101710128223 Chloride channel protein Proteins 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 241000239269 Leiurus Species 0.000 description 1
- 241000239268 Leiurus quinquestriatus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 101710111876 Neurotoxin BmK CT Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150070926 ct gene Proteins 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000003257 protein preparation method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种靶向性抗胶质瘤蛋白质，是以实验证实的蝎氯离子通道神经毒素(Cltx和BmK CT)在治疗脑神经胶质瘤中的途径(抑制氯通道ClC和MMP-2的活性)为基础，利用SWISS-MODEL服务器对BmK CT进行蛋白质原子结构的同源建模，并利用ZDOCK服务器进行氯通道毒素与受体复合物的原子结构模建，在候选模型中筛选结构稳定的模型并进行能量最小化和分子动力学分析，通过对Cltx和BmK CT的结合能量及氢键结合次数的分析，构建以氯通道毒素空间结构为骨架优化设计的新型具有对神经胶质瘤细胞高选择性和高特异性的蛋白分子序列和模型。本发明蛋白质可用于制备治疗神经胶质瘤的药物。The present invention provides a targeted anti-glioma protein, which is the approach (inhibition of chloride channel ClC and MMP- 2) as the basis, use the SWISS-MODEL server to carry out the homologous modeling of the protein atomic structure of BmK CT, and use the ZDOCK server to carry out the atomic structure modeling of the chloride channel toxin and receptor complex, and screen the structure in the candidate model A stable model and energy minimization and molecular dynamics analysis were performed. Through the analysis of the binding energy and hydrogen bond number of Cltx and BmK CT, a new type of glioma-resistant glioma was constructed based on the optimal design of the space structure of chloride channel toxin. Protein molecular sequences and models with high selectivity and specificity for cells. The protein of the invention can be used to prepare medicine for treating neuroglioma.
Description
Technical field
The present invention relates to protein amino acid sequence, specifically is a kind of targeting antiglioma protein and the application of this protein in preparation treatment neuroglia tumor medicine based on scorpion chloride channel toxin.
Background technology
See that on the whole the present stage mankind still are in the exploratory stage for the treatment of malignant tumour.Monoclonal antibody medicine and gene therapy are still difficult as people's will, but the development of studying with gene biological of finishing along with the Human Genome Project, human more understandings and assurance to tumor invasion mechanism and correlation properties, the individual special catabolic cancer treatment method that discovery brought of the specific antigens that cancer cells is more, more stable will make monoclonal antibody medicine and gene therapy become the main trend of oncotherapy.
2003, U.S. Sonthrimer finds that isolating a kind of catilan Cltx can suppress the neuroglial cytoma growth effectively from Israel's scorpion toxin, and the infiltration and the mechanism of Cltx anti-glioma cell explored, confirmed that at glioma cell film surface expression, the matrix metalloproteinase-2 (MMP-2) that plays an important role in tumour cell diffusion be the bind receptor of Cltx, Cltx can be by suppressing the diffusion of tumour cell in conjunction with MMP-2.Chinese scholar finds to have a kind of neurotoxin BmK CT in buthus martensii Karscs in research buthus martensii Karscs toxin process, infer that according to the high sequence homology of itself and Cltx its function class is similar to Cltx.
This seminar is consulting on the basis of relative literature, has carried out the research of BmK CT albumen anti-glioma, has obtained progress preferably.We at first utilized the bypass method synthetic improvement BmK CT gene, realized that it efficiently expresses in intestinal bacteria, and this gene order is granted national inventing patent (a kind of scorpion chloride channel neurotoxin gene-rBmK CTa of synthetic, the patent No.: 200410012544.6,2009 years).Secondly, detect reorganization scorpion toxin rBmKCTa to the human glioma cell SHG-44 of cultivation and the influence of normal mice neurogliocyte, confirm that it has specific effect to neuroglial cytoma with mtt assay.And, utilize full cell patch tongs technology to prove conclusively the electrophysiological property of rBmK CTa, be the chloride channel inhibitor.At last, adopt radioactivity
131This toxin of I mark, foundation moves the nude mice animal model of growing the neuroglial cytoma that the people is arranged, followed the trail of the trend of this toxin in animal model, confirmed rBmK CTa be a kind of molecular weight little, can pass the blood brain and organize barrier, and can be in vivo and the pharmaceutical protein (bioactivity research of buthus martensii Karscs chloride channel toxin of the acceptor target position specific combination of tumor tissues, the doctorate paper, Yin Litian, 2009).
Above analytical proof, Cltx and BmK CT can be used as the active drug of potential mark and treatment glioma brain tumour and develop.But as the small molecular protein medicine, the research of this class catilan and acceptor (chloride channel protein and MMP-2 albumen) molecular mechanism of action does not still have report at present, illustrated and have only when the interactional molecule mechanism between them, just can help us further to utilize and transform this proteinoid, strengthen the specific effect of itself and target cell.The present invention utilizes protein structure database PDB, SwissModel server by the exploitation of Switzerland information biology institute, ZDOCK server by the research and development of U.S. BOSTON university, associated biomolecule information science resources such as Biopolymer and Discover3 software package among the Insight II of Accelrys company, at protein structure and function prediction, the interaction of protein molecule and dynamic molecular are simulated this experiment bottleneck problem, carried out the molecular computing modeling effort of catilan and acceptor interaction, make up the 3 d structure model of important molecule incident in this process, by optimizing the part amino acid sites, made up the active drug molecular model and the sequence that have more target, the research and development of novel anti neuroglia tumor medicine have been had important theory be worth and application prospect.
Summary of the invention
The object of the present invention is to provide a kind of targeting antiglioma protein and the application of this protein in preparation treatment neuroglia tumor medicine based on scorpion chloride channel toxin.
A kind of targeting antiglioma protein provided by the invention, aminoacid sequence are SEQ ID No.5.
This targeting antiglioma protein preparation method comprises the steps:
(1) (derives from Israel scorpion (Leiurus quinquestriatus) with protein C ltx, its aminoacid sequence is seen SEQ IDNo.1) and insect toxin 15A (PDB numbering: 1SIS) structure that is provided is the basis, carry out the homology modeling of BmK CT protein (derive from buthus martensii Karscs (Buthus matensii Karsch), its aminoacid sequence is seen SEQ ID No.2) atomic structure and do energy minimization and molecular dynamics optimization;
(2) utilize V.3.7 software of DeepView, adopt the Coulomb computation schema, calculate the electrostatic potential of Cltx, BmK CT protein surface;
(3) the X-ray crystallographic structural analysis result of the ligand binding domain of the receptor protein that provides according to the PDB storehouse, be chloride channel PROTEIN C lC-2C end cytoplasmic region and MMP-2 PROTEIN C end structure, with above-mentioned operational pattern, calculate its surface electrostatic gesture, and analyze and can get, very likely there is electrostatic attraction between Cltx/BmK CT and its acceptor CLC-2C end and the MMP-2C end molecule;
(4) the atomic structure mould that utilizes the ZDOCK server to carry out Cltx/BmK CT and acceptor ClC-2C and MMP-2C mixture is built, and ZDOCK result done energy minimization and analysis on Molecular Dynamics, final every kind of butt joint complex body obtains 10 candidate's models, obtains the total energy of each model;
(5) frequency of each amino acid and acceptor formation hydrogen bond in statistics Cltx, BmK CT and acceptor ClC-2, the MMP-2 combination model;
(6), design respectively at ClC-2,4 new protein amino acid sequences that the MMP-2 joint efficiency is the highest according to the result of (5):
CCL1(SEQ?ID?No.3)：
MCMPCFTTDHQMARKCRECCGGKGRC
FGPQCLCR
CCL2(SEQ?ID?No.4)：
MCMPCFTTDHQMARKCRECCGGKGRC
YGPQCLCR
CMM1(SEQ?ID?No.5)：
MCGPCFTTDH
QMARKCRECCGGKGRCYGPQCLCR
CMM2(SEQ?ID?No.6)：
MCGPCFTTDH
NMARKCRECCGGKGRCYGPQCLCR
(7) detect new protein sequence and receptors bind parameter, can 4 indexs sign and estimate newly-designed protein sequence from mixture hydrogen bond quantity, the electrostatic interaction of the mixture total energy of energy minimum, average total energy, energy minimum;
(8), determine that finally CMM1 (SEQ ID No.5) is the targeting antiglioma protein sequence according to more little stable more, many more stable more, the big more stable more principles of static potential energy absolute value of hydrogen bonded quantity of complex body total energy.
CMM1 provided by the invention (SEQ ID No.5) targeting antiglioma protein confirms to improve propagation and the diffusion that suppresses neuroglial cytoma by computer simulation, can use in preparation treatment neuroglia tumor medicine.
Description of drawings
Fig. 1: BmK CT albumen space atomic diagram (A) and space secondary structure Pareto diagram (B)
The electrostatic potential of Fig. 2: Cltx, BmK CT protein surface
Fig. 3: chloride channel PROTEIN C lC-2C end cytoplasmic region and MMP-2C end structure and surface electrostatic gesture thereof
Each amino acid and acceptor form the frequency of hydrogen bond in Fig. 4: Cltx, BmK CT and acceptor ClC-2C, the MMP-2C combination model
Fig. 5: design at ClC-2C, new protein amino acid sequence that the MMP-2C joint efficiency is the highest
Position (A) and Gly3 the position (B) in CMM1 three-dimensional structure of Fig. 6: Met3 in the CCL2 three-dimensional structure
Embodiment
1, the homology modeling of PROTEIN B mK CT atomic structure: scorpion toxin Cltx has the solution space conformation of resolving by NMR accordingly in the protein structure proximity database (pdb) proximity (the PBD numbering: 1CHL), and BmK CT does not have.Therefore, need homology modeling server by Swiss Model, based on homologous protein Cltx and insect toxin 15A (PDB numbering: the 1SIS) structure that is provided, BmK CT albumen and template are carried out sequence alignment, the operational method and the energy minimization principle of utilization atom mechanics, with the formwork structure is fundamental construction BmK CT space atomic structure model, and the Discover3 software package obtains BmK CT albumen space atomic diagram (Figure 1A) and space secondary structure Pareto diagram (Figure 1B) after doing energy minimization and analysis on Molecular Dynamics in Insight II.The parameter that the Discover3 software package is done energy minimization among the Insight II is set to:
Water box, temperature 298K, maximum step time (Max Step) be that 3000 times, the final degree of convergence (Final Convergence) are 0.001, conjugation method (Conjugate-Method) is the Polak-Ribiere method; The analysis on Molecular Dynamics parameter is set to: temperature 298K, step-length (Time Step) are to be 1fs, working time (Run Time) 150ps.White expression carbon atom C, sky-blue are that hydrogen atom H, avy blue are nitrogen-atoms N, the red Sauerstoffatom O of being among Figure 1A, yellow expression hydrogen bond.
2, utilize (the Swiss Institute of Bioinformatics of Switzerland bioinformation association, SIB) DeepView that provides is software V.3.7, adopt the Coulomb computation schema, with ± 1.8kT/e is a standard, calculates the electrostatic potential (see figure 2) of Cltx, BmK CT protein surface.
Shown in Fig. 2 A, Cltx is made of a α-helix and two antiparallel β-sheet, and this tertiary structure with present known short chain scorpion toxin is consistent.The surface electrostatic potential analysis shows that the Cltx surface arrangement a large amount of positive potentials, and the basic aminoacids in the hint molecule and the positive potential of generation play a decisive role to itself and receptors bind.This phenomenon is in BmK CT (Fig. 2 B) equally.
3, the X-ray crystallographic structural analysis result of the ligand binding domain of the receptor protein that provides according to the PDB storehouse, be chloride channel PROTEIN C lC-2C end cytoplasmic region and MMP-2C end structure, with above-mentioned operational pattern, calculate its surface electrostatic gesture (see figure 3), the electrostatic force that produces by electric field analyzes these two acceptors and interactional possibility takes place the chloride channel toxin.
The cytoplasmic region of ClC-2 can be divided into the class glutaredoxin structural domain of two structural domain: N ends and the structural domain (Fig. 3 A) of whole α of being-helix that C holds.Tart " foot loop " district that is positioned at the C end is the peculiar structure of people ClCs family.From Fig. 3 B, because the existence of 6 acidic residues is arranged, foot loop district is strong negative potential; And be positioned at N and C end intermediary groove positively charged gesture, show that these two sites may be the zones with its ligand interaction.
MMP-2C end regions (MMP-2C, Thr
458-Cys
660) be a compact form (Fig. 3 C) of forming by the albumen of 4 foliated lamellar β propeller samples, 4 middle holes that surround a channel-like of lamella, Ca
2+And Na-Cl
-To passing through.The surface electrostatic potential analysis shows that negative potential mainly is distributed in (Fig. 3 D) on I, II, the IV lamella.
As above analyze, very likely have electrostatic attraction between Cltx/BmK CT and its acceptor ClC-2C end and the MMP-2C end molecule.
4, the atomic structure mould that utilizes the ZDOCK server of U.S. BOSTON university to carry out Cltx/BmK CT and acceptor ClC-2C end and MMP-2C end mixture is built.Utilize that Biopolymer and Discover3 software package do energy minimization and analysis on Molecular Dynamics to ZDOCK result among the Insight II, do optimization with method of steepest descent,
Do 300 step conjugate gradient energy minimizations in the water box, having done step-length at 298K is 1fs, the analysis on Molecular Dynamics (MD) that amounts to 5000fs, all operations under CVFF (consistent-valence force field) field of force function of above process.Final every kind of butt joint complex body obtains 10 candidate's models.List the total energy of every kind of butt joint complex body in the table 1.
The total energy of 10 candidate's models of table 1 butt joint complex body
*
| The mixture title | ??1 | ??2 | ??3 | ??4 | ??5 | ??6 | ??7 | ??8 | ??9 | ??10 |
| ??Cltx-ClC-2C | ??8827.708 | ??8787.235 | ??8824.385 | ??8936.501 | ??8891.536 | ??8852.775 | ??8712.011 | ??8870.135 | ??8733.026 | ??8796.467 |
| ??BmK?CT??-ClC-2C | ??8675.524 | ??8818.053 | ??8710.359 | ??8802.362 | ??8786.077 | ??8830.029 | ??8723.958 | ??8784.826 | ??8661.587 | ??8734.667 |
| ??Cltx-MMP-2C | ??8867.521 | ??8810.024 | ??8794.646 | ??8835.639 | ??8781.633 | ??8855.765 | ??8795.532 | ??8704.685 | ??8867.731 | ??8854.332 |
| ??BmK?CT-??MMP-2C | ??8753.638 | ??8721.404 | ??—— | ??8802.211 | ??8791.389 | ??8845.689 | ??8661.025 | ??8815.227 | ??8801.841 | ??8751.346 |
(
*Total energy is kinetic energy and potential energy sum, and unit is kcal/mol;---expression is owing to the compatibling problem between software causes calculating the result.)
5, the frequency (see figure 4) of each amino acid and acceptor formation hydrogen bond in statistics Cltx, BmK CT and acceptor ClC-2C, the MMP-2C combination model.
6,, design respectively at ClC-2C, 4 new protein amino acid sequence (see figure 5)s that the MMP-2C joint efficiency is the highest according to the result of Fig. 4.
7, detect new protein sequence and receptors bind parameter: utilize ZDOCK server, Insight II software package that newly-designed protein sequence is done with ClC-2C, MMP-2C to dock, energy minimization and analysis on Molecular Dynamics, sign and estimate newly-designed protein sequence (seeing Table 2,3,4) from mixture hydrogen bond quantity, these a few indexs of electrostatic interaction energy of the mixture total energy of energy minimum, average total energy, energy minimum.
Table 2 has been listed new design protein sequence docks 10 candidate's models of complex body with acceptor total energy; Table 3 listed in Cltx/BmK CT before and after the sequence optimisation combine on average total energy and energy minimum with the ClC-2C end two complex bodys join, the comparison of hydrogen bond position, quantity and the electrostatic interaction energy of acceptor interaction; Table 4 listed in Cltx/BmK CT before and after the sequence optimisation combine on average total energy and energy minimum with the MMP-2C end two complex bodys join, the comparison of hydrogen bond position, quantity and the electrostatic interaction energy of acceptor interaction.
The new design of table 2 protein sequence docks the total energy of 10 candidate's models of complex body with acceptor
*
| The mixture title | ??1 | ??2 | ??3 | ??4 | ??5 | ??6 | ??7 | ??8 | ??9 | ??10 |
| ??CCL1-??ClC-2C | ??8692.494 | ??8711.141 | ??8634.207 | ??8623.221 | ??8755.685 | ??8707.374 | ??8782.786 | ??8717.297 | ??8711.211 | ??8774.209 |
| ??CCL2-??ClC-2C | ??8691.543 | ??8782.683 | ??8712.545 | ??8635.346 | ??8607.804 | ??8677.652 | ??8719.005 | ??8713.295 | ??8788.054 | ??8639.399 |
| ??CMM1??-MMP-2C | ??8691.614 | ??8711.593 | ??8673.626 | ??8550.030 | ??8675.108 | ??8691.341 | ??8635.214 | ??8694.564 | ??8641.591 | ??8675.535 |
| ??CMM2??-MMP-2C | ??8665.936 | ??8630.769 | ??8701.186 | ??8607.310 | ??—— | ??8621.717 | ??8626.319 | ??8655.476 | ??8574.467 | ??8523.503 |
(
*Total energy is kinetic energy and potential energy sum, and unit is kcal/mol;---expression is owing to the compatibling problem between software causes calculating the result.)
Before and after table 3 sequence optimisation Cltx/BmK CT combine with ClC-2C in two complex bodys of on average total energy and energy minimum join, the comparison (wherein power unit is kcal/mol) of hydrogen bond position, quantity and the electrostatic interaction energy of acceptor interaction
Before and after table 4 sequence optimisation Cltx/BmK CT combine with MMP-2C in two complex bodys of on average total energy and energy minimum join, the comparison (wherein power unit is kcal/mol) of hydrogen bond position, quantity and the electrostatic interaction energy of acceptor interaction
8, according to more little stable more, many more stable more, the big more stable more principles of static potential energy absolute value of hydrogen bonded quantity of complex body total energy, filtering out following 2 sequences is optimal sequence:
CCL2(SEQ?ID?No.4)：
MC
MPCFTTDHQMARKCRECCGGKGRCYGPQCLCR
CMM1(SEQ?ID?No.5)：
MC
GPCFTTDHQMARKCRECCGGKGRCYGPQCLCR
By sequence as can be known, the difference of these two sequences only is the 3rd amino acids difference, from the structure (see figure 6), square frame is depicted as Met3 in the CCL2 three-dimensional structure of Fig. 6 A, square frame is depicted as Gly3 in the CMM1 three-dimensional structure of Fig. 6 B, these two amino-acid residues all are positioned at the position that the N end does not form secondary structure, influence to its three-dimensional structure is also little, so in conjunction with other index, on function, can effectively suppress the neuroglial cytoma migration from it and consider, determine that the CMM1 sequence is final a kind of targeting antiglioma protein sequence based on scorpion chloride channel toxin.
A kind of targeting antiglioma protein sequence based on scorpion chloride channel toxin provided by the invention confirms to improve propagation and the diffusion that suppresses neuroglial cytoma by computer simulation.
SEQUENCE?LISTING
＜110〉University Of Shanxi
＜120〉targeting antiglioma protein and application thereof
<130>.
<160>6
<170>PatentIn?version?3.5
<210>1
<211>36
<212>PRT
<213>Leiurus?quinquestriatus
<400>1
Met?Cys?Met?Pro?Cys?Phe?Thr?Thr?Asp?His?Gln?Met?Ala?Arg?Lys?Cys
1???????????????5???????????????????10??????????????????15
Asp?Asp?Cys?Cys?Gly?Gly?Lys?Gly?Arg?Gly?Lys?Cys?Tyr?Gly?Pro?Gln
20??????????????????25??????????????????30
Cys?Leu?Cys?Arg
35
<210>2
<211>36
<212>PRT
<213>Buthus?matensii?Karsch
<400>2
Met?Cys?Gly?Pro?Cys?Phe?Thr?Thr?Asp?Ala?Asn?Met?Ala?Arg?Lys?Cys
1???????????????5???????????????????10??????????????????15
Arg?Glu?Cys?Cys?Gly?Gly?Ile?Gly?Lys?Cys?Phe?Gly?Pro?Gln?Cys?Leu
20??????????????????25??????????????????30
Cys?Asn?Arg?Ile
35
<210>3
<211>34
<212>PRT
<213>Aritifical
<400>3
Met?Cys?Met?Pro?Cys?Phe?Thr?Thr?Asp?His?Gln?Met?Ala?Arg?Lys?Cys
1???????????????????5???????????????10??????????????????15
Arg?Glu?Cys?Cys?Gly?Gly?Lys?Gly?Arg?Cys?Phe?Gly?Pro?Gln?Cys?Leu
20??????????????????25??????????????????30
Cys?Arg
<210>4
<211>34
<212>PRT
<213>Aritifical
<400>4
Met?Cys?Met?Pro?Cys?Phe?Thr?Thr?Asp?His?Gln?Met?Ala?Arg?Lys?Cys
1???????????????5???????????????????10??????????????????15
Arg?Glu?Cys?Cys?Gly?Gly?Lys?Gly?Arg?Cys?Tyr?Gly?Pro?Gln?Cys?Leu
20??????????????????25??????????????????30
Cys?Arg
<210>5
<211>34
<212>PRT
<213>Aritifical
<400>5
Met?Cys?Gly?Pro?Cys?Phe?Thr?Thr?Asp?His?Gln?Met?Ala?Arg?Lys?Cys
1???????????????5???????????????????10??????????????????15
Arg?Glu?Cys?Cys?Gly?Gly?Lys?Gly?Arg?Cys?Tyr?Gly?Pro?Gln?Cys?Leu
20??????????????????25??????????????????30
Cys?Arg
<210>6
<211>34
<212>PRT
<213>Aritifical
<400>6
Met?Cys?Gly?Pro?Cys?Phe?Thr?Thr?Asp?His?Asn?Met?Ala?Arg?Lys?Cys
1???????????????5???????????????????10??????????????????15
Arg?Glu?Cys?Cys?Gly?Gly?Lys?Gly?Arg?Cys?Tyr?Gly?Pro?Gln?Cys?Leu
20??????????????????25??????????????????30
Cys?Arg
Claims (2)
1. targeting antiglioma protein, its aminoacid sequence is SEQ ID No.5.
2. the application of targeting antiglioma protein as claimed in claim 1 in preparation treatment neuroglia tumor medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010144841A CN101824084A (en) | 2010-04-08 | 2010-04-08 | Targeting antiglioma protein and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010144841A CN101824084A (en) | 2010-04-08 | 2010-04-08 | Targeting antiglioma protein and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101824084A true CN101824084A (en) | 2010-09-08 |
Family
ID=42688269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010144841A Pending CN101824084A (en) | 2010-04-08 | 2010-04-08 | Targeting antiglioma protein and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101824084A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778310B2 (en) | 2005-04-22 | 2014-07-15 | University Of Washington | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
| US9018347B2 (en) | 2010-02-04 | 2015-04-28 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
| US9023595B2 (en) | 2008-05-15 | 2015-05-05 | Morphotek, Inc. | Treatment of metastatic tumors |
| US9944683B2 (en) | 2010-05-11 | 2018-04-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| CN107936084A (en) * | 2017-11-01 | 2018-04-20 | 十堰市太和医院 | A kind of production method for the CAP23145 polypeptides based on targeting FMRP for treating glioma |
| US10156559B2 (en) | 2012-12-10 | 2018-12-18 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| CN111440771A (en) * | 2020-03-17 | 2020-07-24 | 中山大学附属第三医院 | A leukoencephalopathy patient-specific induced pluripotent stem cell line harboring a homozygous mutation in CLCN2 |
| WO2022144560A1 (en) * | 2020-12-30 | 2022-07-07 | Vascular Venture Korlátolt Felelősségű Társaság | Chlorotoxin derivatives and use thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| CN117059158A (en) * | 2023-07-10 | 2023-11-14 | 国开启科量子技术(安徽)有限公司 | Method, device, equipment and medium for extracting protein attribute characteristics |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| CN119400280B (en) * | 2024-09-29 | 2025-10-17 | 南京邮电大学 | Drug molecule virtual screening method based on binding mode analysis |
-
2010
- 2010-04-08 CN CN201010144841A patent/CN101824084A/en active Pending
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8778310B2 (en) | 2005-04-22 | 2014-07-15 | University Of Washington | Fluorescent chlorotoxin conjugate and method for intra-operative visualization of cancer |
| US9023595B2 (en) | 2008-05-15 | 2015-05-05 | Morphotek, Inc. | Treatment of metastatic tumors |
| US9603952B2 (en) | 2008-05-15 | 2017-03-28 | Morphotek, Inc. | Treatment of metastatic tumors |
| US10183975B2 (en) | 2010-02-04 | 2019-01-22 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
| US9018347B2 (en) | 2010-02-04 | 2015-04-28 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
| US9234015B2 (en) | 2010-02-04 | 2016-01-12 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
| US9637526B2 (en) | 2010-02-04 | 2017-05-02 | Morphotek, Inc. | Chlorotoxin polypeptides and conjugates and uses thereof |
| US9944683B2 (en) | 2010-05-11 | 2018-04-17 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| US10822381B2 (en) | 2010-05-11 | 2020-11-03 | Fred Hutchinson Cancer Research Center | Chlorotoxin variants, conjugates, and methods for their use |
| US10156559B2 (en) | 2012-12-10 | 2018-12-18 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US12048750B2 (en) | 2013-09-17 | 2024-07-30 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US12048732B2 (en) | 2016-04-15 | 2024-07-30 | Blaze Bioscience, Inc. | Methods of treating breast cancer |
| CN107936084A (en) * | 2017-11-01 | 2018-04-20 | 十堰市太和医院 | A kind of production method for the CAP23145 polypeptides based on targeting FMRP for treating glioma |
| CN111440771A (en) * | 2020-03-17 | 2020-07-24 | 中山大学附属第三医院 | A leukoencephalopathy patient-specific induced pluripotent stem cell line harboring a homozygous mutation in CLCN2 |
| WO2022144560A1 (en) * | 2020-12-30 | 2022-07-07 | Vascular Venture Korlátolt Felelősségű Társaság | Chlorotoxin derivatives and use thereof |
| CN117059158A (en) * | 2023-07-10 | 2023-11-14 | 国开启科量子技术(安徽)有限公司 | Method, device, equipment and medium for extracting protein attribute characteristics |
| CN117059158B (en) * | 2023-07-10 | 2025-07-15 | 国开启科量子技术(安徽)有限公司 | Method, device, equipment and medium for extracting protein attribute characteristics |
| CN119400280B (en) * | 2024-09-29 | 2025-10-17 | 南京邮电大学 | Drug molecule virtual screening method based on binding mode analysis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101824084A (en) | Targeting antiglioma protein and application thereof | |
| Niu et al. | A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain | |
| Ojha et al. | High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19 | |
| Zhang et al. | Hantavirus infections in humans and animals, China | |
| Webby et al. | Protection and compensation in the influenza virus-specific CD8+ T cell response | |
| Luan et al. | Insights into SARS-CoV-2’s mutations for evading human antibodies: sacrifice and survival | |
| US20130064843A1 (en) | Identification of conserved peptide blocks in homologous polypeptides | |
| نصرتی et al. | A novel multi-epitope vaccine for cross protection against hepatitis C virus (HCV): An immunoinformatics approach | |
| Dey et al. | Latency antigen α-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokines | |
| Chen et al. | Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma | |
| Hurtado et al. | Deep repertoire mining uncovers ultra-broad coronavirus neutralizing antibodies targeting multiple spike epitopes | |
| BR0308103A (en) | DNA vaccine against proliferating endothelial cells and methods of using this | |
| Ye et al. | Cytokine Storm in Acute Viral Respiratory Injury: Role of Qing-Fei-Pai-Du Decoction in Inhibiting the Infiltration of Neutrophils and Macrophages through TAK1/IKK/NF-κ B Pathway | |
| Shin et al. | Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38 | |
| Yu et al. | The p15 protein is a promising immunogen for developing protective immunity against African swine fever virus | |
| Horváth et al. | Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage | |
| CN103320451A (en) | Genetic engineering protein vaccine for preventing EV71, and preparation method thereof | |
| CN105950646A (en) | Construction method and application of avian influenza universal vaccine with spore probiotics as mucosal delivery vector | |
| Ghosh et al. | Genome-wide analysis of Indian SARS-CoV-2 genomes to identify T-cell and B-cell epitopes from conserved regions based on immunogenicity and antigenicity | |
| Alabbas | Integrativesubtractive proteomics, immunoinformatics, docking, and simulation approaches reveal candidate vaccine against Sin Nombre orthohantavirus | |
| Kuraoka et al. | Hide and seek: interplay between influenza viruses and B cells | |
| Liang et al. | Restoring Tumor Cell Immunogenicity Through Ion‐Assisted p53 mRNA Domestication for Enhanced In Situ Cancer Vaccination Effect | |
| Gao et al. | Two new species of Parastagonospora and a new species of Phaeoseptoriella (Phaeosphaeriaceae, Pleosporales) from grasslands in Yunnan Province, China | |
| CN106279393A (en) | A kind of GP96 method for purifying proteins | |
| Nandy et al. | Towards Personalized Vaccines—Tailoring Peptide Vaccines to Demographic Groups and Individuals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100908 |